Document is current

Article History

Received: 23 July 2019

Accepted: 3 June 2020

First Online: 8 July 2020

Ethics approval and consent to participate

: The study was approved by the local ethics committee at each participating site. Details on each study site and affiliated ethics committee study approval are provided in Additional file . All patients alive at the time of chart abstraction (99% of patients) signed an informed consent form prior to participation in this study. No data from a deceased patient were included in the reported analyses.

: Not applicable.

: UH: Lecture fee(s) and consultancy: AbbVie, MSD, Ferring, Falk Foundation, Takeda, Mundipharma, Hospira, Vifor Pharma, Biogen, Pfizer, Shield Therapeutics, Janssen.MM: Consultancy: AbbVie, Takeda, MSD, Falk, Janssen, Pfizer.SS: Lecture fees: AbbVie, MSD, Falk, Ferring, Takeda, Janssen; consultancy: MSD, Janssen, Takeda, AbbVie.HH: Lecture fees: AbbVie, MSD, Falk, Ferring, Takeda; consultancy: AbbVie, Janssen, Takeda.AB: Employee of Takeda Pharma Vertrieb GmbH & Co. KG; holds Takeda stock or stock options.DS: Employee of Evidera, which received funds from Takeda to conduct the research.CK: Employee of Takeda Pharmaceuticals International AG; holds Takeda stock or stock options.JK: Employee of Takeda Pharma Vertrieb GmbH & Co. KG; holds Takeda stock or stock options.SCH: Employee of Takeda UK Limited; holds Takeda stock or stock options.RE: Lecture fee(s): AbbVie, Pfizer, MSD, Falk, Ferring, Takeda, Janssen, Hospira, Shield Therapeutics, Vifor Pharma, Tillotts Pharma AG, Recordati SpA, Norgine, Microbiotica, Ardeypharm; consultancy: MSD, Biogen, Ferring, Takeda, Janssen, AbbVie, Tillotts Pharma AG, Novartis.